US Patent

US9233103 — Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy

Method of Use · Assigned to Takeda Pharmaceuticals USA Inc · Expires 2032-03-05 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating heartburn and preventing gastric bleeding or hemorrhage in patients taking clopidogrel therapy.

USPTO Abstract

The present invention relates to methods of treating heartburn in a patient receiving clopidogrel therapy. In another aspect, the present invention relates to methods of preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy.

Drugs covered by this patent

Dexilant (DEXLANSOPRAZOLE) · Takeda

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1805`	—	Dexilant
`U-1805`	—	Dexilant

Patent Metadata

Patent number: US9233103
Jurisdiction: US
Classification: Method of Use
Expires: 2032-03-05
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceuticals USA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.